Literature DB >> 30343342

IgG levels in Kawasaki disease and its association with clinical outcomes.

Marco Antonio Yamazaki-Nakashimada1, Luisa Berenise Gámez-González2, Chiharu Murata3, Takafumi Honda4, Kumi Yasukawa4, Hiromichi Hamada4.   

Abstract

Previous studies have suggested an association of IgG levels (before and after IVIG infusion) with clinical outcomes in Kawasaki disease. A retrospective analysis was performed that included 418 patients with KD admitted to Tokyo Women's Medical University Yachiyo Medical Center to evaluate pre- and post-IVIG IgG levels and its relation to outcomes. All patients received an initial IVIG infusion and aspirin; IgG levels were measured in 350 patients before IVIG (pre-IVIG IgG levels) and in 373 patients 48 h after starting IVIG infusion (post-IVIG IgG levels). Media and standard deviation of the pre- and post-IVIG IgG levels were reported and classified according to age. Also, IgG z-scores were calculated according to normal values of IgG by age. The number of cases and corresponding percentage of non-responders were reported by age and total patients. The association of pre-IVIG, post-IVIG IgG levels and post-IVIG IgG level/pre-IVIG IgG level ratio with no-response was evaluated by simple logistic regression model based on the IgG z-score, and regression coefficient, X2 value, p, and R2 of Nagelkerke were reported. Pre-IVIG and post-IVIG IgG levels presented an association with non-responders with statistical significance. This association was more evident between post-IVIG IgG levels and non-responders. Regarding coronary alterations, it was not possible to perform an adequate statistical analysis due the small number of patients. Pre- and post-IVIG infusion IgG levels could be an important biomarker in KD as well as in other inflammatory conditions. Higher IgG levels could be associated with a more effective immunomodulatory action and associated with better clinical outcomes.

Entities:  

Keywords:  IgG; IgG levels; Intravenous immunoglobulins; Kawasaki disease

Mesh:

Substances:

Year:  2018        PMID: 30343342     DOI: 10.1007/s10067-018-4339-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.

Authors:  Ja-Young Hwang; Kyung-Yil Lee; Jung-Woo Rhim; You-Sook Youn; Jin-Hee Oh; Ji-Whan Han; Joon-Sung Lee; David Burgner
Journal:  Arch Dis Child       Date:  2010-06-15       Impact factor: 3.791

2.  Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies.

Authors:  Jordan S Orange; William J Grossman; Roberta J Navickis; Mahlon M Wilkes
Journal:  Clin Immunol       Date:  2010-08-01       Impact factor: 3.969

3.  The treatment of Kawasaki syndrome with intravenous gamma globulin.

Authors:  J W Newburger; M Takahashi; J C Burns; A S Beiser; K J Chung; C E Duffy; M P Glode; W H Mason; V Reddy; S P Sanders
Journal:  N Engl J Med       Date:  1986-08-07       Impact factor: 91.245

4.  Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki Disease.

Authors:  S Nishihara; K Ishibashi; K Iribe; I Matsuda
Journal:  Lancet       Date:  1988-10-22       Impact factor: 79.321

5.  Coronary risks after high-dose gamma-globulin in children with Kawasaki disease.

Authors:  Y Morikawa; Y Ohashi; K Harada; T Asai; S Okawa; M Nagashima; T Katoh; K Baba; K Furusho; M Okuni; M Osano
Journal:  Pediatr Int       Date:  2000-10       Impact factor: 1.524

6.  Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.

Authors:  Kosuke Yanagimoto; Yuichi Nomura; Kiminori Masuda; Masako Hirabayashi; Yasuko Morita; Michiko Yoshishige; Kentaro Ueno; Taisuke Eguchi; Yoshifumi Kawano
Journal:  Int Arch Allergy Immunol       Date:  2014-06-04       Impact factor: 2.749

7.  Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP.

Authors:  Pieter A van Doorn; Krista Kuitwaard; Bart C Jacobs
Journal:  J Peripher Nerv Syst       Date:  2011-06       Impact factor: 3.494

8.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.

Authors:  J W Newburger; M Takahashi; A S Beiser; J C Burns; J Bastian; K J Chung; S D Colan; C E Duffy; D R Fulton; M P Glode
Journal:  N Engl J Med       Date:  1991-06-06       Impact factor: 91.245

9.  Prognostic impact of vascular leakage in acute Kawasaki disease.

Authors:  Masaru Terai; Takafumi Honda; Kumi Yasukawa; Kouji Higashi; Hiromichi Hamada; Yoichi Kohno
Journal:  Circulation       Date:  2003-06-30       Impact factor: 29.690

10.  Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.

Authors:  Krista Kuitwaard; Jenny de Gelder; Anne P Tio-Gillen; Wim C J Hop; Teun van Gelder; Albert W van Toorenenbergen; Pieter A van Doorn; Bart C Jacobs
Journal:  Ann Neurol       Date:  2009-11       Impact factor: 10.422

View more
  4 in total

1.  Identification of rare coding variants associated with Kawasaki disease by whole exome sequencing.

Authors:  Jae-Jung Kim; Young Mi Hong; Sin Weon Yun; Kyung-Yil Lee; Kyung Lim Yoon; Myung-Ki Han; Gi Beom Kim; Hong-Ryang Kil; Min Seob Song; Hyoung Doo Lee; Kee Soo Ha; Hyun Ok Jun; Byung-Ok Choi; Yeon-Mok Oh; Jeong Jin Yu; Gi Young Jang; Jong-Keuk Lee
Journal:  Genomics Inform       Date:  2021-12-31

Review 2.  Hygiene Hypothesis as the Etiology of Kawasaki Disease: Dysregulation of Early B Cell Development.

Authors:  Jong-Keuk Lee
Journal:  Int J Mol Sci       Date:  2021-11-15       Impact factor: 5.923

3.  Hygienic behaviors during the COVID-19 pandemic may decrease immunoglobulin G levels: Implications for Kawasaki disease.

Authors:  Hiromi Yamaguchi; Masaaki Hirata; Kuniya Hatakeyama; Ichiro Yamane; Hisashi Endo; Hiroe Okubo; Yoshimi Nishimura; Yoshiro Nagao
Journal:  PLoS One       Date:  2022-09-28       Impact factor: 3.752

4.  Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial.

Authors:  Saori Fukui; Mitsuru Seki; Takaomi Minami; Kazuhiko Kotani; Kensuke Oka; Akiko Yokomizo; Daisuke Matsubara; Tomoyuki Sato; Yasuyuki Nozaki; Mari Saito; Yutaka Kikuchi; Kenji Miyamoto; Yukifumi Monden; Takanori Yamagata
Journal:  Pediatr Rheumatol Online J       Date:  2021-07-03       Impact factor: 3.054

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.